Kailera Therapeutics vs Mirador Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kailera Therapeutics (Hengrui spinout) raised $1B+ and filed a US IPO (Mar 2026); its lead GLP-1/GIP drug showed 18% weight loss in Phase 3, competing with Mounjaro and Zepbound.
About
Kailera Therapeutics is a clinical-stage biopharmaceutical company spun out of Chinese pharma giant Hengrui Pharmaceuticals, focused on developing next-generation obesity and metabolic disease treatments. Founded to advance a promising portfolio of GLP-1 and GIP-based drug candidates into the US market, Kailera brings a differentiated pipeline built on Hengrui's extensive metabolic disease research, adapted and developed for global regulatory standards and patient populations.\n\nKailera's lead asset is a dual GLP-1/GIP receptor agonist targeting obesity and type 2 diabetes, the same mechanism underlying blockbuster drugs like Mounjaro and Zepbound. In Phase 3 clinical trials, the drug demonstrated 18% average weight loss — a result that positions it competitively against existing approved therapies. The company is pursuing US FDA approval through a standard NDA pathway, targeting the massive and rapidly growing market for prescription obesity medications where demand continues to outpace supply.\n\nKailera filed for a US IPO in March 2026, having raised over $1B in private financing to fund its clinical development program. The Phase 3 weight loss data and the scale of the obesity drug market — projected to exceed $100B annually by the late 2020s — give the IPO strong fundamental support. As GLP-1 drugs redefine the treatment of obesity, metabolic disease, and potentially cardiovascular and neurological conditions, Kailera's differentiated asset and substantial clinical progress position it as a credible entrant in one of biopharma's most competitive and lucrative races.
Raised $250M Series B (Jan 2026). $650M+ total raised. Mirador360 genetics-first platform. 10+ clinical readouts by end of 2027. Pipeline spans Crohn's, ulcerative colitis, RA, IPF.
About
Mirador Therapeutics is a precision immunology company with a genetics-first platform (Mirador360) that uses human genetic data to identify the most biologically validated targets and patient subpopulations for inflammatory and fibrotic diseases. The company closed a $250 million Series B in January 2026, bringing total funding above $650 million, with an ambitious pipeline targeting Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis (IPF). Ten or more clinical readouts are expected by end of 2027.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.